<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

AACR 2023 Poster 2387

Characterization of Orthotopic Bioluminescent Patient-derived Xenograft Model of Glioma for Drug Discovery

Jinxi Wang, Ling Chen, Jun Zhou, Likun Zhang, Jinyu Huang, Xueluan Zhu, Ludovic Bourre, Jessie J.J. Wang
Crown Bioscience Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127

Gliomas account for the majority of primary brain tumors and are composed of different grades, which present distinct molecular alterations, histological characteristics and response to treatments. Subcutaneously inoculated glioma patient-derived xenograft (PDX) models provide convenient evaluation of treatment efficacy, but do not mimic the in situ microenvironment, blood-brain barrier permeability, and diffuse invasive growth to peripheral tissue in the brain. Orthotopic intracranial implantation of bioluminescent labelled glioma PDX models provides a more physiologically relevant preclinical model to evaluate and quantify treatment response, however it is challenging to ensure the quality and viability of glioma cells after prolonged in vitro culture. In this study, a strategy of combining short term in vitro transduction followed by in vivo expansion and passaging was adopted to establish a bioluminescent glioma PDX model, BN2289-Luc, for the orthotropic study of glioma.

Download this Poster to Discover:

  • Methods for establishing orthotopic bioluminescent PDX models

  • Characterization of established model BN2289-Luc in vivo using bioluminescence imaging and histological study

  • In vivo efficacy study data for orthotopic BN2289-Luc model

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.